Robert N J
New England Medical Center, Boston.
Hosp Pract (Off Ed). 1990 Oct 15;25(10):93-8, 101-2. doi: 10.1080/21548331.1990.11704022.
With increasing options for adjuvant therapy in breast cancer, it is even more important to know which patients are at risk for recurrent disease. Variables such as tumor size and node status are well-established markers. Others have recently been proposed. Will these new markers improve our ability to assess prognosis and select appropriate management modalities?
